If you have UnitedHealthcare coverage and your gastroenterologist has prescribed Entyvio for Crohn's disease, the practical question is whether your plan will pay and what you have to do to get there. The short answer is that UnitedHealthcare does cover Entyvio for Crohn's disease for members who meet its clinical criteria, but coverage is not automatic. The drug requires prior authorization, and you generally have to document that you tried and did not respond well to conventional treatment first. Understanding how UnitedHealthcare structures that review, and what your own plan documents say, is the difference between a smooth approval and a frustrating denial. This guide walks through the coverage mechanics, the typical prior authorization criteria, and what to do if you are turned down.
What Entyvio Is and Why Coverage Has Rules
Entyvio, the brand name for vedolizumab, is an integrin receptor antagonist approved for moderately to severely active Crohn's disease and ulcerative colitis. It works differently from older biologics by binding to the alpha-4-beta-7 integrin, which blocks certain white blood cells from migrating into gut tissue. Because that target is concentrated in the gastrointestinal tract, Entyvio is often described as gut-selective. Treatment begins with intravenous infusions at weeks zero, two, and six, then every eight weeks, and in April 2024 the FDA approved a subcutaneous maintenance option for Crohn's disease that patients can self-inject after IV induction. Specialty biologics like this carry a high cost, which is why insurers apply prior authorization and require documentation before approving them.
How UnitedHealthcare Structures Entyvio Coverage
UnitedHealthcare runs its pharmacy benefit through OptumRx and dispenses specialty drugs through Optum Specialty Pharmacy, and the benefit your Entyvio falls under depends on how it is given. The intravenous form is administered in a clinic or infusion center, so it typically runs through the medical benefit rather than the pharmacy benefit. UnitedHealthcare states that Optum manages prior authorization for certain medical benefit injectable medications for commercial members, and infused specialty drugs commonly sit in this provider-administered category. The self-injected subcutaneous pen, by contrast, is more likely to be handled through the pharmacy benefit and dispensed by a specialty pharmacy. This distinction matters because it determines whether your costs apply to your medical deductible or your pharmacy cost-sharing, and which prior authorization pathway your prescriber uses. Your own plan's documents will confirm which benefit applies to you.
Typical Prior Authorization Criteria for Crohn's
UnitedHealthcare's published commercial policy spells out what it looks for. According to the UnitedHealthcare Commercial Medical Benefit Drug Policy for Entyvio, initial approval for Crohn's disease requires a documented diagnosis of moderately to severely active disease plus one of two pathways. The policy describes these as a history of failure, contraindication, or intolerance to at least one conventional therapy, or corticosteroid dependence.
The conventional therapies named in the policy include:
A tumor necrosis factor blocker such as adalimumab or certolizumab
An immunomodulator such as azathioprine or 6-mercaptopurine
A corticosteroid
The same policy notes that Entyvio must be dosed according to FDA labeling and is not approved in combination with other targeted immunomodulators, and that initial authorization is issued for no more than 12 months. These are the published commercial criteria, and your specific plan may apply additional rules.
Why Documentation Drives the Decision
The criteria above are essentially a documentation test. UnitedHealthcare is asking your gastroenterologist to show, in the medical record, that you have moderately to severely active Crohn's disease and that you meet one of the qualifying pathways. That means dated records of the corticosteroids, immunomodulators, or anti-TNF biologics you tried, what happened on each, and why they were stopped. The clinical rationale aligns with current practice. The 2025 AGA living guideline on moderate-to-severe Crohn's disease lists vedolizumab among recommended options and supports upfront use of advanced therapy over prolonged step-up with corticosteroids alone. A prior authorization that includes your diagnosis, disease activity, prior treatment history with outcomes, and the FDA-labeled dosing plan gives the reviewer everything the policy asks for. Gaps in that record are the most common reason a request stalls.
What to Do If UnitedHealthcare Denies Entyvio
A denial is not the end of the road, and many are reversed on appeal once the missing documentation is supplied. Federal rules give you the right to an internal appeal when an insurer denies coverage, and the HealthCare.gov guidance on internal appeals explains that an insurer must tell you in writing why a prior authorization request was denied, generally within 15 days, and that you can submit additional information to support your case. If the internal appeal is unsuccessful, you can request an external review by an independent reviewer whose decision the plan must follow. Start by reading the denial letter to identify the exact reason, then ask your gastroenterologist to add the specific records the reviewer needs, such as documentation of a failed conventional therapy or steroid dependence. A focused appeal that answers the stated criteria directly is far more persuasive than a general request to reconsider.
The Bottom Line for UnitedHealthcare Members
UnitedHealthcare does cover Entyvio for Crohn's disease, but approval depends on prior authorization and on documenting that you meet the plan's clinical criteria, which generally include moderately to severely active disease and a failure of or dependence on conventional therapy. Because the intravenous form usually runs through the medical benefit and the subcutaneous pen through the pharmacy benefit, your exact costs and pathway depend on how your treatment is given and on the specifics of your plan. The most reliable way to know where you stand is to pull your own plan's formulary and medical policy documents, confirm the current Entyvio criteria, and work with your gastroenterologist to assemble a complete treatment history before the request is submitted. Doing that groundwork upfront is what turns a yes-or-no question into a clear path to approval.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.